1. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Issue 10323 (29th January 2022) Authors: Bravo, Lulu; Smolenov, Igor; Han, Htay Htay; Li, Ping; Hosain, Romana; Rockhold, Frank; Clemens, Sue Ann Costa; Roa, Camilo; Borja-Tabora, Charissa; Quinsaat, Antoinette; Lopez, Pio; López-Medina, Eduardo; Brochado, Leonardo; Hernández, Eder A; Reynales, Humberto; Medina, Tatiana; Velasquez, Hect... Journal: Lancet Issue: Volume 399:Issue 10323(2022) Page Start: 461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2022) Authors: Hardt, Karin; Vandebosch, An; Sadoff, Jerald; Le Gars, Mathieu; Truyers, Carla; Lowson, David; Van Dromme, Ilse; Vingerhoets, Johan; Kamphuis, Tobias; Scheper, Gert; Ruiz-Guiñazú, Javier; Faust, Saul N; Spinner, Christoph D; Schuitemaker, Hanneke; Van Hoof, Johan; Douoguih, Macaya; Struyf, Frank;... Journal: Lancet infectious diseases Issue: Volume 22:Issue 12(2022) Page Start: 1703 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study. Issue 11 (10th March 2023) Authors: Buntinx, Erik; Brochado, Leonardo; Borja-Tabora, Charissa; Yu, Charles Y.; Alberto, Edison R; Montellano, May Emmeline B.; Carlos, Josefina C.; Toloza, Leonardo Bautista; Hites, Maya; Siber, George; Clemens, Ralf; Ambrosino, Donna; Qin, Haijing; Chen, Hui Ling; Han, Htay Htay; Hu, Branda; Li, Pin... Journal: Vaccine Issue: Volume 41:Issue 11(2023) Page Start: 1875 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗